Goldline Pharmaceutical Limited
ListedSMEHealthcare · BSE
Goldline Pharmaceuticals markets pharmaceutical products under the “Goldline” brand, offering a wide range of medicines across five divisions—Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness. These products cater to various medical specialties including physicians, cardiologists, pediatricians, orthopedics, neurologists, critical care experts, and cancer supportive care. Instead of manufacturing medicines directly, the company works with third-party manufacturers who produce products based on its research and specifications while ensuring quality and regulatory compliance. Goldline sells its products through a network of distributors, retailers, and wholesalers, and also supports hospitals and healthcare providers with procurement and supply services. The company currently partners with 15 manufacturers and 7 distributors, with operations spread across states like Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar.
Price Band
₹41 – ₹43
Issue Size
₹270.00 L Cr
Lot Size
3000 shares
GMP
₹12
+27.9%
Est. Listing
₹55
at current GMP
Subscribed
840.81x
overall
Open
12 May 2026
Close
14 May 2026
Allotment
15 May 2026
Refund
16 May 2026
Demat Credit
17 May 2026
Listing
19 May 2026
Last updated 4 months ago
Overall Subscription
840.81x
Total Demand
QIB Multiplier
180.22x
Institutions & Funds
NII / HNI
1662.39x
High Net-Worth
Retail (RII)
881.15x
Individual Bidders
Category-Wise Subscription Breakup
Live bidding breakdown by institutional, non-institutional, and retail investors
| Category | Shares Offered | Shares Applied / Bid | Times Subscribed |
|---|---|---|---|
| QIB | 540,000 | 97,317,000 | 180.22x |
| NIB | 390,000 | 648,333,000 | 1662.39x |
| HNIs(10L +) | 260,000 | 518,874,000 | 1995.67x |
| HNIs (2-10L) | 130,000 | 129,459,000 | 995.84x |
| RETAIL | 900,000 | 793,038,000 | 881.15x |
| Total | 2,220,000 | 2,187,021,000 | 840.81x |
Application-Wise Breakup
Total unique applications received across retail and HNI tranches
| Category | Applications Reserved | Applications Received | Times Subscribed |
|---|---|---|---|
| QIB | — | 85 | 0.00x |
| NIB | — | 33,760 | 0.00x |
| RETAIL | 150 | 132,173 | 881.15x |
| EMPLOYEES | — | — | 0.00x |
| HNIs(10L +) | 29 | 20,429 | 704.45x |
| HNIs (2-10L) | 14 | 13,331 | 952.21x |
| Shareholder | — | — | 0.00x |
| Total Applications | 193 | 199,778 | 1035.12x |
Day-Wise Subscription Progress
About Goldline Pharmaceutical Limited Public Issue & Market Profile
Goldline Pharmaceutical Limited is bringing an initial public offering (IPO) in the Healthcare sector with an aggregate issue size of ₹27,00,000 Crores. The shares are offered at a price band of ₹41 to ₹43 per equity share on BSE. Currently, investors are tracking the grey market premium (GMP) and institutional subscription multiples closely across BSE and NSE portals.
Bidding & Quota Instructions:
The public offer consists of a fresh issue and offer-for-sale structured under SEBI regulations. Bidding is open to Qualified Institutional Buyers (QIB), Non-Institutional Bidders (NII/HNI), and Retail Individual Investors (RII). Applications can be submitted online using ASBA or UPI mandate through certified stock brokers and net banking portals.
Allotment Reconciliation Schedule:
Following the close of bidding on 2026-05-14, the basis of allotment is scheduled to be finalized on 2026-05-15. Investors can verify their application status online by submitting their PAN card number, Application Number, or DP Client ID on the registrar's official portal (Bigshare Services Private Limited) or the BSE allotment checking window.
Frequently Asked Questions
What is the issue size and price band for Goldline Pharmaceutical Limited IPO?
The Goldline Pharmaceutical Limited IPO aggregate issue size is ₹27,00,000 Crores with an equity price band set at ₹41 to ₹43 per equity share. The retail lot size is 3000 shares requiring a minimum capital outlay of approx. ₹1,29,000.
How can I check Goldline Pharmaceutical Limited IPO live subscription demand?
Live subscription figures are compiled real-time from the NSE and BSE bidding engines. You can track QIB, NII/HNI, and Retail category multiples directly on our dedicated live subscription page.
Where will Goldline Pharmaceutical Limited IPO allotment status be published?
The basis of allotment will be published on the official registrar portal (Bigshare Services Private Limited) and the BSE status verification website on or around 2026-05-15.